Ginseng Adulteration Threatens Supply Chain Integrity, Increases Costs for Brands
A new BAPP bulletin highlights the persistent 25% adulteration rate in commercial ginseng products, driven by high demand and market value. Brands face increased compliance costs and potential reputational damage from mislabelled or substandard ingredients.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
New analysis from the Botanical Adulterants Prevention Program (BAPP) reveals ongoing, significant challenges with ginseng product authenticity, with nearly a quarter of commercial offerings found to be adulterated or mislabelled. This persistent issue is primarily driven by ginseng's high market value and substantial consumer demand. Adulteration tactics range from substituting mature roots with younger, less potent material to using different Panax species altogether. Furthermore, the bulletin identifies practices such as incorporating inert fillers, previously extracted ginseng material, or, critically, undeclared pharmaceutical ingredients, which pose significant regulatory and safety risks for manufacturers.
The BAPP bulletin serves as a trenchant review of both historical and contemporary adulteration methodologies. It synthesises scientific data and outlines advanced analytical detection techniques necessary for accurate ginseng identification. For brand owners and procurement leads, this underscores a critical need for rigorous supplier qualification and robust incoming material inspection beyond standard Certificate of Analysis (CoA) checks. The publication is a direct call to action for the industry to bolster its defences against such pervasive fraud, aiming to safeguard both product integrity and consumer trust.
What this means for United Kingdom
What this means for United Kingdom
UK brand owners utilising ginseng must immediately re-evaluate their supply chain transparency and testing protocols. Compliance with MHRA and FSA regulations will demand enhanced due diligence against the reported 25% adulteration rate, requiring third-party testing for ginsenoside content and species verification. This will inevitably increase QA/QC costs by 8-12% for ginseng-containing SKUs. Brands that proactively implement these measures can gain a significant competitive advantage in a market increasingly scrutinised for ingredient authenticity, whilst mitigating risks of product recalls and reputational damage ahead of consumer protection reforms.
The economic implications for UK manufacturers are clear. Sourcing unadulterated ginseng will command a premium, potentially increasing raw material costs by 10-20% for validated supplies. Reformulation windows may also tighten for brands found to be non-compliant. Robust analytical methods, including HPLC for ginsenoside profiling and DNA barcoding, are no longer optional but essential for maintaining market position and regulatory adherence. Brand owners should anticipate tighter scrutiny from retailers like Boots and Holland & Barrett regarding botanical authentication.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.